--- title: "Tvardi Therapeutics (TVRD) news: reverse split and merger" url: "https://aibio.space/companies/tvardi-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "TVRD reverse split and merger news: Cara Therapeutics (now Tvardi Therapeutics) closes merger with Tvardi, 1-for-3 reverse split. Tvardi Therapeutics, Inc." --- TVRD Tvardi Therapeutics, Inc. NASDAQ · United States # Tvardi Therapeutics (TVRD) news TVRD reverse split and merger news Mergers · 2025-04-15 ## [Cara Therapeutics (now Tvardi Therapeutics) closes merger with Tvardi, 1-for-3 reverse split](https://aibio.space/news/cara-therapeutics-now-tvardi-therapeutics-closes-merger-tvardi-1-3/) Cara Therapeutics completed its merger with Tvardi on April 15, 2025 and took the Tvardi name after a 1-for-3 reverse stock split. Former Cara holders keep about 15.4% of the combined company, and the cash plan runs into the second half of 2026 on the strength of two Phase 2 readouts that have not yet been reported. ## Latest Tvardi Therapeutics news 1. 2025-04-01 Mergers [Cara Therapeutics (now Tvardi Therapeutics) stockholders approve Tvardi merger share issuance](https://aibio.space/news/cara-therapeutics-now-tvardi-therapeutics-stockholders-approve-tvardi/) Cara stockholders approved the share issuance for the merger with Tvardi, a reverse split range of 1-for-2 to 1-for-4, and an increase in authorized shares to 150,000,000. 2. 2024-12-18 Mergers [Cara Therapeutics (now Tvardi Therapeutics) agrees all-stock merger with private Tvardi](https://aibio.space/news/cara-therapeutics-now-tvardi-therapeutics-agrees-all-stock-merger/) Cara Therapeutics agreed on December 18, 2024 to combine with private Tvardi Therapeutics in an all-stock deal. Pre-merger Cara holders would own about 17.0% of the combined company, and the closing depends on Cara holding at least $18.0 million of net cash. ## Tvardi Therapeutics at a glance - **Ticker**: TVRD - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $15.8 million ### Related companies - [Kalaris Therapeutics](https://aibio.space/companies/kalaris-therapeutics/) NASDAQ: KLRS - [MBX Biosciences](https://aibio.space/companies/mbx-biosciences/) NASDAQ: MBX - [Nurix Therapeutics](https://aibio.space/companies/nurix-therapeutics/) NASDAQ: NRIX - [Xeris Biopharma Holdings](https://aibio.space/companies/xeris-biopharma/) NASDAQ: XERS - [Amgen](https://aibio.space/companies/amgen/) NASDAQ: AMGN - [ADMA Biologics](https://aibio.space/companies/adma-biologics/) NASDAQ: ADMA - [Frontage Holdings](https://aibio.space/companies/frontage/) HKEX: 1521 - [Senti Biosciences Holdings](https://aibio.space/companies/senti-biosciences/) NASDAQ: SNTI ### Also on NASDAQ - [EDAP TMS SA](https://aibio.space/companies/edap-tms/) FOCL - [KESTRA MEDICAL TECHNOLOGIES, LTD.](https://aibio.space/companies/kestra-medical-technologies/) KMTS - [Clene](https://aibio.space/companies/clene/) CLNN - [Aura Biosciences](https://aibio.space/companies/aura-biosciences/) AURA - [ASP Isotopes](https://aibio.space/companies/asp-isotopes/) ASPI - [Orthofix Medical](https://aibio.space/companies/orthofix-medical/) OFIX ## Tvardi Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$18.0 million](https://www.sec.gov/Archives/edgar/data/1346830/000110465926037729/) | [$23.6 million](https://www.sec.gov/Archives/edgar/data/1346830/000110465926037729/) | | Net income (loss) | [-$18.2 million](https://www.sec.gov/Archives/edgar/data/1346830/000110465926037729/) | [-$29.4 million](https://www.sec.gov/Archives/edgar/data/1346830/000110465926037729/) | | Cash from operations | [-$23.5 million](https://www.sec.gov/Archives/edgar/data/1346830/000110465926037729/) | [-$18.3 million](https://www.sec.gov/Archives/edgar/data/1346830/000110465926037729/) | | Cash and equivalents | [$20.7 million](https://www.sec.gov/Archives/edgar/data/1346830/000110465926096424/) | [$31.6 million](https://www.sec.gov/Archives/edgar/data/1346830/000110465926037729/) | | Short-term investments | [$10.1 million](https://www.sec.gov/Archives/edgar/data/1346830/000110465926096424/) | | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $15.8 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Tvardi Therapeutics Did Tvardi Therapeutics do a reverse stock split? Our latest story on this, dated Apr 15, 2025: "Cara Therapeutics (now Tvardi Therapeutics) closes merger with Tvardi, 1-for-3 reverse split". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cara-therapeutics-now-tvardi-therapeutics-closes-merger-tvardi-1-3/). Is Tvardi Therapeutics involved in a merger or acquisition? Our latest story on this, dated Apr 15, 2025: "Cara Therapeutics (now Tvardi Therapeutics) closes merger with Tvardi, 1-for-3 reverse split". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cara-therapeutics-now-tvardi-therapeutics-closes-merger-tvardi-1-3/). What is the ticker symbol of Tvardi Therapeutics? Tvardi Therapeutics, Inc. trades under the ticker TVRD on NASDAQ. Where is Tvardi Therapeutics listed? Tvardi Therapeutics, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:69C. What is the SEC CIK of Tvardi Therapeutics? The SEC Central Index Key (CIK) for Tvardi Therapeutics, Inc. is 1346830. Its filings are on SEC EDGAR. How many shares does Tvardi Therapeutics have outstanding? 13,338,943 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Tvardi Therapeutics listed under? Our directory records Tvardi Therapeutics, Inc. under United States. What does Tvardi Therapeutics do? Our directory classifies Tvardi Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Tvardi Therapeutics? The ISIN recorded for Tvardi Therapeutics, Inc. is US1407553072. Does aibio.space cover Tvardi Therapeutics? aibio.space lists Tvardi Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Tvardi Therapeutics incorporated? SEC records list its state or country of incorporation as DE. Is Tvardi Therapeutics profitable? Tvardi Therapeutics, Inc. reported a net loss of $18.2 million for the fiscal year ended Dec 31, 2025, and used $23.5 million of cash in operations, per its annual report to the SEC. How much does Tvardi Therapeutics spend on research and development? $18.0 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Tvardi Therapeutics have? $15.8 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Tvardi Therapeutics (TVRD) stock news? Our latest story on Tvardi Therapeutics, dated Apr 15, 2025: "Cara Therapeutics (now Tvardi Therapeutics) closes merger with Tvardi, 1-for-3 reverse split". Cara Therapeutics completed its merger with Tvardi on April 15, 2025 and took the Tvardi name after a 1-for-3 reverse stock split. Former Cara holders keep about 15.4% of the combined company, and the cash plan runs into the second half of 2026 on the strength of two Phase 2 readouts that have not yet been reported. [Source](https://aibio.space/news/cara-therapeutics-now-tvardi-therapeutics-closes-merger-tvardi-1-3/). ## Investor discussion: Tvardi Therapeutics Members talk about Tvardi Therapeutics (TVRD). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Tvardi Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-07-17 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1346830/000110465926084619/tm2620412-1_424b5.htm) 2. 2025-05-30 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1346830/000110465925054853/tvrd-20250331xs1.htm) 3. 2025-05-13 Legal Reported a change of independent auditor. SEC Form 8-K (Items 2.02,4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1346830/000110465925047856/tm2514879d1_ex99-1.htm) 4. 2025-05-13 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1346830/000155837025007575/tvrd-20250331x10q.htm) 5. 2025-04-01 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1346830/000110465925030583/tm2510381d1_ex99-1.htm) 6. 2025-03-11 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1346830/000155837025002705/cara-20241231x10k.htm) 7. 2025-01-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1346830/000110465925004517/tm2430195d6_8k.htm) 8. 2024-12-30 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1346830/000110465924132481/tm2430195d4_8k.htm) 9. 2024-12-18 Mergers Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,5.01,5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1346830/000110465924129596/tm2431150d1_ex99-1.htm) 10. 2024-11-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1346830/000110465924122099/tm2429290d1_8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:TVRD on TradingView](https://www.tradingview.com/symbols/NASDAQ-TVRD/). ## SEC filings and registration - **SEC name**: Tvardi Therapeutics, Inc. - **CIK**: 1346830 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: TVRD (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 3 SUGAR CREEK CTR. BLVD., SUGAR LAND, TX, 77478 - **Phone**: (713) 489-8654 - **Shares outstanding**: 13,338,943 as of 2026-08-11 (10-Q filed 2026-08-14) - **Former names**: Cara Therapeutics, Inc.; Cara Therapeutics Inc ### Recent filings (8-K and 6-K are the company's own announcements) - [10-Q](https://www.sec.gov/Archives/edgar/data/1346830/000110465926096424/tvrd-20260630x10q.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1346830/000110465926096417/tm2623143d1_8k.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1346830/000110465926088461/tm2621651d1_8k.htm) filed 2026-07-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1346830/000110465926084627/tm2620743d1_8k.htm) filed 2026-07-17 - [424B5](https://www.sec.gov/Archives/edgar/data/1346830/000110465926084619/tm2620412-1_424b5.htm) filed 2026-07-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1346830/000110465926080930/tm2619879d1_8k.htm) filed 2026-07-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1346830/000110465926072930/tm2617528d1_8k.htm) filed 2026-06-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/1346830/000110465926057528/tvrd-20260331x10q.htm) filed 2026-05-08 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001346830), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Tvardi Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker TVRD, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Tvardi Therapeutics, Inc. - **Ticker**: TVRD - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US1407553072 - **Other listed symbols**: GETTEX:69C - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-TVRD/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/tvardi-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Tvardi Therapeutics (TVRD) news: reverse split and merger", 2026-10-31, https://aibio.space/companies/tvardi-therapeutics/